This phase III, single center, randomized controlled trial enrolled eligible patients undergoing radical radiotherapy for node-negative prostate adenocarcinoma, with estimated nodal risk ≥ 20%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback